Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Junior Research Group Immune Regulation in Cancer

Dr. Chong Sun

Dissect antitumor T cell immunity for more effective cancer immunotherapy (click to enlarge)
© dkfz.de

Research Focus:
Our lab studies the interplay between T cells and tumors, with a particular focus on the molecular mechanisms that compromise T cell-mediated immune response to tumors, a critical component of antitumor immunity.

Specifically, 1) insufficient T cell trafficking into tumors, 2) compromised T cell activation, and 3) tumor cell resistance to T cell cytotoxicity collectively contribute to immune evasion in cancer and limit the effectiveness of T cell-based immunotherapies. Our primary objective is to systematically identify and understand the molecular mechanisms that contribute to these processes in the tumor microenvironment or intrinsically within T cells.

Approaches and objectives:
Our lab employs physiologically or clinically relevant cell and mouse models to recapitulate the individual processes that compromise antitumor T cell immunity, including T cell trafficking, modulation of T cell functions, and tumor cell response to T cell attack.

We then use or develop function-based genomic methods, such as genetic and chemical screening, in combination with state-of-the-art technologies to systematically identify and comprehend the molecular determinants underlying these individual processes. Finally, we evaluate the translational potential of our findings using in vivo and ex vivo tumor models.

Our aim is to contribute to the understanding of molecular and cellular mechanisms that regulate antitumor T cell response and bridge the gap between basic research and clinical translation, thus facilitating the development of more effective therapeutic strategies for cancer immunotherapy.

Contact

Dr. Chong Sun
Immune Regulation in Cancer (D250)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
69120 Heidelberg
Tel: +49 6221 42 3432

Selected Publications

  • Sun, C.*, Mezzadra, R.* & Schumacher, T. N.* Regulation and Function of the PD-L1 Checkpoint. Immunity 48, 434-452, doi:10.1016/j.immuni.2018.03.014 (2018).
  • Mezzadra, R.*, Sun, C.*, Jae, L. T.*, Gomez-Eerland, R., de Vries, E., Wu, W., Logtenberg, M. E. W., Slagter, M., Rozeman, E. A., Hofland, I., Broeks, A., Horlings, H. M., Wessels, L. F. A., Blank, C. U., Xiao, Y., Heck, A. J. R., Borst, J., Brummelkamp, T. R. & Schumacher, T. N. M. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 549, 106-110, doi:10.1038/nature23669 (2017).
  • Sun, C*., Wang, L.*, Huang, S.*, Heynen, G. J., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., Zecchin, D., Hobor, S., Bajpe, P. K., Lieftink, C., Mateus, C., Vagner, S., Grernrum, W., Hofland, I., Schlicker, A., Wessels, L. F., Beijersbergen, R. L., Bardelli, A., Di Nicolantonio, F., Eggermont, A. M. & Bernards, R. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508, 118-122, doi:10.1038/nature13121 (2014).
  • Miao, B*; Hu, Z*; Mezzadra, R*; Hoeijmakers, L*; Fauster, A; Du, S; Yang, Z; Sator-Schmitt, M; Engel, H; Li, X; Broderick, C; Jin, G; Gomez-Eerland, R; Rozeman, L; Lei, X; Matsuo, H; Yang, C; Hofland, I; Peters, D; Broeks, A; Laport, E; Fitz, A; Zhao, X; Mahmoud, M. A. A; Ma, X; Sander, S; Liu, H. K; Cui, G; Gan, Y; Wu, W; Xiao, Y; Heck, A. J. R; Guan, W; Lowe, S. W; Horlings, H. M; Wang, C; Brummelkamp, T. R; Blank, C. U#; Schumacher, T. N. M.# & Sun, C#. CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1. Cancer Cell 41, 1-12, doi:10.1016/j.ccell.2023.08.008 (2023).
to top
powered by webEdition CMS